



Gary Schwartz, MD
Co-Chair for Experimental Therapeutics Committee
Columbia University
177 Fort Washington Avenue, Suite 6GN-435
New York, NY 10032
Phone: 212-305-2055
Email: Schwartzg@columbia.edu

Charles Erlichman, MD, FRCPC, FACP
Co-Chair for Experimental Therapeutics Committee
Mayo Clinic
200 First Street SW
Rochester, MN 55905
Phone: 507-266-3200
Email: Erlichman.charles@mayo.edu

Date: Friday, October 16, 2015

To: Experimental Therapeutics Committee

From: Gary Schwartz, M.D.
Charles Erlichman, M.D.

Re: **Experimental Therapeutics Committee Meeting**

Date: **Friday, November 6, 2015**

Time: **7:00am-10:00am Central**

Location: Loews Chicago O'Hare - Rosemont, IL 60018
Room Guggenheim 2

Call In Information: (800) 501-8979 / Access Code: 8087368

AGENDA

1. Status of Concepts: *Schwartz or Horvath*

a.	Safety and activity of pembrolizumab, alone or with chemotherapy, combined with radiation in patients with metastatic carcinoma of unknown primary	H. Yoon
----	--	---------

2. Status update on activated current trials: *Horvath*

a.	A091302	Randomized Phase II study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
b.	A091305	A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
c.	A091101	Carboplatin-paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) – A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	J. de Souza
d.	A091102 (permanently closed to accrual)	Phase II Study of MLN8237 in Advanced Metastatic Sarcoma	M. Dickson
e.	A091104 (permanently closed to enrollment)	A Phase II Study of MK-2206 in Patients with Progressing Recurrent/Metastatic Adenoid Cystic Carcinoma	A. Ho
f.	A091105	A Phase III Double Blind Randomized, Placebo Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)	M. Gounder
g.	A091201	Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma	J. Luke
h.	A091202	A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian
i.	A091401 (suspended to pre-registration)	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo
j.	N0871 (permanently closed to enrollment)	A Phase II Study of Carbopatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)	M. Goetz
k.	N0879 (permanently closed to enrollment)	A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma	R. McWilliams
l.	N1153	Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC	M. Borad

3. Status update on current trials in development: *Schwartz or Horvath*

a.	A091304	A Phase I/Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced/Unresectable and/or Metastatic Sarcoma	W. Tap
b.	A091404	A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers	A. Ho

4. Status of Concepts: *Schwartz or Horvath*

a.	B Smart		E. Horvath
b.	Reversing Resistance to Pazopanib with Histone Deacetylase Inhibition		P. Munster
c.	A Randomized Trial of Adjuvant Pembrolizumab, Adjuvant Chemotherapy, or Expectant Observation following Neoadjuvant Pembrolizumab and Surgical Resection of High-Risk Localized or Locoregionally Advanced Mucosal Melanoma.		R. Carvajal A. Shoushtari
d.	Randomized Phase III Trial: Adjuvant anti-PD-1 therapy for 1 year versus observation in patients with a Castle Biosciences Class 2 high risk for relapse Primary Cutaneous Melanoma With T(2a-4a)N0M0		L. Geskin
e.	PD1/PDL1 + antiCD20 in recurrent Head and Neck Cancer		M. Matsangou

5. Update on NCI Sponsored Match – *Schwartz*

6. Alliance Updates - *Horvath*

- Accrual Initiatives: Network ACT
- Member Services Task Force